News
MYGN
27.65
-0.72%
-0.20
U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Colgate-Palmolive, McKesson, Microsoft and Air Products & Chemicals among those. AIG, AIG and others have seen their target prices cut by some analysts.
Reuters · 3d ago
Weekly Report: what happened at MYGN last week (0715-0719)?
Weekly Report · 4d ago
Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?
Myriad Genetics, Inc. (NASDAQ:MYGN) has US$38.7m of debt, but has more cash than debt. The company has more liabilities than assets, but its balance sheet is healthy. Myriad Genetics lost US$235m in the last year, but managed to grow its revenue by 11%. The company does carry debt, which is a risky sign for a company with a high level of debt. But the company's future is more important than its debt levels.
Simply Wall St · 07/17 16:55
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
63% of women do not know that there is an increased risk of breast cancer for women with dense breasts. Myriad Genetics, Inc. Released results from its nationwide Cancer Risk Survey: Breast Cancer Edition. The survey focused on understanding the role of breast density and cancer risk in the U.S.
Barchart · 07/17 07:00
U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. BlackRock, Goldman Sachs and Netflix revise their ratings and targets on Tuesday. Broadcom, Amazon.com and American Tower among companies with new targets. Some of the companies have announced stock splits.
Reuters · 07/16 07:29
MYRIAD GENETICS INC <MYGN.O>: TD COWEN RAISES TARGET PRICE TO $28 FROM $23
Reuters · 07/16 04:13
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
NASDAQ · 07/15 18:01
Weekly Report: what happened at MYGN last week (0708-0712)?
Weekly Report · 07/15 09:10
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
NASDAQ · 07/10 11:53
MYRIAD GENETICS ANNOUNCES SECOND FOUNDATIONAL PATENT GRANTED FOR MOLECULAR RESIDUAL DISEASE (MRD) WITH EARLY PRIORITY DATE
Reuters · 07/09 13:00
Weekly Report: what happened at MYGN last week (0701-0705)?
Weekly Report · 07/08 09:10
Weekly Report: what happened at MYGN last week (0624-0628)?
Weekly Report · 07/01 09:10
Myriad Genetics started at sector outperform at Scotiabank on addressable markets
Myriad Genetics started at sector outperform at Scotiabank on addressable markets. The firm has a $29 price target for the stock. Myriad Genetics is focused on molecular diagnostic tests for the oncology, women's health, and pharmacogenomics sectors. The company is trading at a discount to other advanced diagnostics companies.
Seeking Alpha · 06/27 16:14
Key Takeaways From Myriad Genetics Analyst Ratings
Myriad Genetics is a molecular diagnostics company that provides tests to assess the risk of developing a disease. The company has a 12-month price target of $28.0. Myriad Genetics has an average of 4 analysts' evaluations of the company. The firm has an impressive financial profile and is a standout performer in its industry.
Benzinga · 06/27 14:00
Myriad Genetics Initiated at Sector Outperform by Scotiabank
Dow Jones · 06/27 13:10
Myriad Genetics Price Target Announced at $29.00/Share by Scotiabank
Dow Jones · 06/27 13:10
U.S. RESEARCH ROUNDUP-Carnival, FedEx, Micron Technology
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Carnival, FedEx and Micron Technology among those with revised targets. FedEx raises target price to $318 from $296; AIG cuts target price. Acadia Pharmaceuticals, Exact Sciences and other companies also see analyst downgrades.
Reuters · 06/27 07:55
MYRIAD GENETICS INC <MYGN.O>: SCOTIABANK INITIATES COVERAGE WITH SECTOR OUTPERFORM RATING; TARGET PRICE $29
Reuters · 06/27 03:45
Myriad Genetics Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution
Myriad Genetics, Inc. Insiders sold US$5.9m worth of shares in the last year. The biggest insider sale was of US$7m to the CEO of the company, Paul Diaz, for US$24.66 per share. In the last 12 months, Myriad Genetics insiders didn't buy any shares. The company owns about 2.3% of myriad Genetics. We found two warning signs for Myriad genetics that deserve your attention.
Simply Wall St · 06/26 10:47
Interesting MYGN Put And Call Options For February 2025
NASDAQ · 06/24 15:59
More
Webull provides a variety of real-time MYGN stock news. You can receive the latest news about Myriad Genetics through multiple platforms. This information may help you make smarter investment decisions.
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.